Detalhe da pesquisa
1.
Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.
Toxicol Appl Pharmacol;
487: 116961, 2024 May 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38740095
2.
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Sci Transl Med;
16(734): eadg7962, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38354229
3.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Oncoimmunology;
12(1): 2205336, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37114242
4.
Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
J Immunother Cancer;
10(12)2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36564128
5.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
iScience;
25(9): 104958, 2022 Sep 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36072551
6.
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Clin Cancer Res;
27(11): 3167-3177, 2021 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33785484